Stoke Therapeutics, Inc. has announced the issuance of stock options to two new employees as part of its compensation package under Nasdaq Listing Rule 5635(c)(4). Effective June 16, 2025, these options allow for the purchase of a total of 37,200 shares at an exercise price of $11.70 per share, matching the closing price of the company's common stock on the same date. The options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly over the subsequent 36 months, contingent upon the employees' continued service. The options have a 10-year term and are governed by the 2023 Inducement Plan and related stock option agreements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.